LYEL - Balance Sheet - Lyell Immunopharma, Inc.

Current Liabilities	53.8 M
Accounts Payable	5.37 M
Short-Term Debt	0
Other Current Liabilities	48.4 M
Non-Current Liabilities	54.2 M
Long-Term Debt	0
Other Non-Current Liabilities	54.2 M

Millions

	Dec-2024	Dec-2023	Dec-2022	Dec-2021	Dec-2020	Dec-2019
ASSETS
Cash & Cash Equivalents	105.6	145.6	123.6	293.8	140.4	96.7
Short Term Investments	264.9	400.6	516.6	321.0	472.2	339.4
Receivables	0	0	0	0	0	0
Inventory	0	0	0	0	0	0
Other Current Assets	9.1	8.5	11.1	23.0	4.9	8.4
Total Current Assets	379.6	554.7	651.3	626.3	617.5	440.3
PP&E	72.9	142.3	166.3	166.6	124.1	43.7
Intangible Assets	0	0	0	0	0	0
Goodwill	0	0	0	0	0	0
Long Term Investments	19.0	48.5	115.0	330.5	163.4	69.0
Other Long Term Assets	19.3	4.5	5.0	3.9	3.2	2.7
Other Assets	0	0	0	0	0	0
Total Assets	490.9	750.0	937.6	1 127.4	908.3	555.6
LIABILITIES
Accounts Payable	5.4	4.8	3.9	3.2	9.4	2.8
Short Term Debt	0	6.3	4.5	1.2	3.6	0.3
Other Current Liabilities	48.4	23.4	28.6	37.4	30.2	14.3
Total Current Liabilities	53.8	34.5	37.0	46.7	49.3	22.0
Long Term Debt	0	56.9	126.3	133.3	51.0	27.1
Deferred Tax Income	0	0	0	0	0	(98.4)
Other Liabilities	54.2	3.7	(59.1)	(62.1)	0.5	0
Total Liabilities	108.0	95.1	104.3	197.6	189.8	147.6
EQUITY
Common Stock	29 K	25 K	25 K	24 K	2 K	1 K
Retained Earnings	(1 345.1)	(1 002.1)	(767.5)	(584.4)	(334.1)	(129.7)
Other Accumulative Comprehensive Income/Loss	0.3	94 K	(7.6)	(1.6)	0.3	0.5
Total Equity	382.8	655.0	833.3	929.8	718.4	408.1
Total Liabilities and Equity	490.9	750.0	937.6	1 127.4	908.3	555.6
SHARES OUTSTANDING
Common Shares Outstanding	261.5	251.0	247.1	242.7	246.6	246.6

Free